Spondyloarthritis & psoriatic arthritis
Inflammatory Bowel Disease Risk in Patients With Axial Spondyloarthritis Treated With Biologic Agents Determined Using the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) and a MetaAnalysis
Pooled result · Incidence of IBD, BSRBR-AS (IRD per 1000 PY)Result — go to the resultIRD 11.9 per 1000 PY 95% CI 4.3–19.6Authors' conclusion
There was an excess risk of IBD among persons treated with biologics in observational studies. Only evidence from RCTs suggested that ETN was associated with an increased risk compared to other anti-TNF therapies, albeit with considerable uncertainty.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) (BSRBR-AS; observational studies and randomized controlled trials (RCTs))
- Comparison
- Biologic therapy vs other therapies; Etanercept (ETN) vs other anti-TNF therapies
- Outcome
- Incidence of IBD; IRD per 1000 PY
Methodological detailsobservational studies and RCTs, BSRBR-AS registry
- Observational studies and RCTs
- BSRBR-AS registry
Pooled result
Incidence of IBD, BSRBR-AS (IRD per 1000 PY)
Incidence rate difference (IRD)
11.9 per 1000 PY
95% CI 4.3–19.6
As reported in the abstract
Further pooled results
| Outcome | IRD (per 1000 PY) (95% CI) |
|---|---|
| Incidence of IBD, placebo-controlled RCTsBiologic therapy vs Not exposed to biologic therapy | 2.2 (−4.1 to 8.5) |
| Incidence of IBD, ETN vs other anti-TNF, BSRBR-AS | −6.5 (−21.3 to 8.5) |
Incidence of inflammatory bowel disease (IBD), placebo-controlled RCTs
- Increased incidence replicated across observational studies
Incidence of IBD, ETN vs other anti-TNF, RCTs and extensions
- Small, not statistically significant absolute increased incidence with ETN (per 1000 person-years (PY))
- between 2.1 and 5.8
Original publication
Inflammatory Bowel Disease Risk in Patients With Axial Spondyloarthritis Treated With Biologic Agents Determined Using the BSRBR-AS and a MetaAnalysis. J Rheumatol. Published 1 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →